{"id":"W4391614640","doi":"10.1007/s10637-023-01410-2","title":"CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; Jewish General Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Randomized controlled trial; Pembrolizumab; Medicine; Antagonist; Internal medicine; Cancer; Immunotherapy; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006799052,0.0002077637,0.000553653,0.0003891884,0.00004297386,0.00007224325,0.00007845514,0.00008333592,0.0001133215],"category_scores_gemma":[0.0001867535,0.00016645,0.0001162297,0.0009002005,0.0002574423,0.000242876,0.00001121757,0.0002940835,0.00001483434],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003621762,"about_ca_system_score_gemma":0.002004729,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006940753,"about_ca_topic_score_gemma":0.0001749941,"domain_scores_codex":[0.9981795,0.0001507435,0.0006245434,0.0003609792,0.0004416776,0.0002425601],"domain_scores_gemma":[0.9992317,0.0003461459,0.0001029652,0.0001357786,0.00005924534,0.0001241623],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9712556,0.0004260075,0.00009174923,0.0001139562,0.0001307317,0.0001389069,0.001934678,0.00007730411,0.01109606,0.004893171,0.0009870504,0.008854807],"study_design_scores_gemma":[0.9756379,0.0009022235,0.0003421688,0.001185005,0.00005494964,0.00009218218,0.00009443353,0.005851313,0.005805613,0.007830329,0.001978552,0.0002253729],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9867374,0.001095603,0.0001586267,0.007933629,0.0002767289,0.002045927,0.00001490145,0.0001012212,0.00163601],"genre_scores_gemma":[0.9960834,0.00006552525,0.000988243,0.0009345713,0.0002200482,0.0002439786,0.0002872996,0.00003248121,0.001144417],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009346083,"threshold_uncertainty_score":0.6787636,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01262812956067111,"score_gpt":0.3092178169209199,"score_spread":0.2965896873602488,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}